Semaxanib (BioDeep_00000837586)
代谢物信息卡片
Semaxanib
化学式: C15H14N2O (238.1106074)
中文名称: 塞马西尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
InChI: InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents
D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
D006133 - Growth Substances > D006131 - Growth Inhibitors
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:91083
- KEGGdrug: D05819
- PubChem: 5329098
- DrugBank: DB06436
- ChEMBL: CHEMBL276711
- CAS: 204005-46-9
- CAS: 194413-58-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Chiao-Yun Chen, Yu-Jung Lin, Charles C N Wang, Yu-Hsuan Lan, Shou-Jen Lan, Ming-Jyh Sheu. Epigallocatechin-3-gallate inhibits tumor angiogenesis: involvement of endoglin/Smad1 signaling in human umbilical vein endothelium cells.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2019 Dec; 120(?):109491. doi:
10.1016/j.biopha.2019.109491. [PMID: 31586903] - Suellen D S Oliveira, Jiwang Chen, Maricela Castellon, Mao Mao, J Usha Raj, Suzy Comhair, Serpil Erzurum, Claudia L M Silva, Roberto F Machado, Marcelo G Bonini, Richard D Minshall. Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF-β (Transforming Growth Factor-β)-Dependent Pulmonary Arterial Hypertension.
Arteriosclerosis, thrombosis, and vascular biology.
2019 06; 39(6):1191-1202. doi:
10.1161/atvbaha.118.312038. [PMID: 30943774] - Rasa Tamosiuniene, Olga Manouvakhova, Paul Mesange, Toshie Saito, Jin Qian, Mrinmoy Sanyal, Yu-Chun Lin, Linh P Nguyen, Amir Luria, Allen B Tu, Joshua M Sante, Marlene Rabinovitch, Desmond J Fitzgerald, Brian B Graham, Aida Habtezion, Norbert F Voelkel, Laure Aurelian, Mark R Nicolls. Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.
Circulation research.
2018 06; 122(12):1689-1702. doi:
10.1161/circresaha.117.312058. [PMID: 29545367] - Xiao-Na Zhu, Yu-Huan Wang, Juan-Juan Wu, Peng Dong, Min Zhang. [Correlation between expressions of VEGF and TRPC6 and their roles in podocyte injury in rats with diabetic nephropathy].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2018 Mar; 38(3):296-304. doi:
NULL. [PMID: 29643035] - Daile Jia, Qian Zhu, Huan Liu, Caojian Zuo, Yuhu He, Guilin Chen, Ankang Lu. Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin αvβ3/FAK/AKT Pathway Suppression.
Circulation. Cardiovascular genetics.
2017 Feb; 10(1):. doi:
10.1161/circgenetics.116.001591. [PMID: 28077433] - Xiangchun Liu, Hong Zhang, Qun Wang, Kezhou Yu, Rong Wang, Jing Sun. Blockade of vascular endothelial growth factor-A/receptor 2 exhibits a protective effect on angiotensin-II stimulated podocytes.
Molecular medicine reports.
2015 Sep; 12(3):4340-4345. doi:
10.3892/mmr.2015.3911. [PMID: 26063200] - Jared M McLendon, Sachindra R Joshi, Jeff Sparks, Majed Matar, Jason G Fewell, Kohtaro Abe, Masahiko Oka, Ivan F McMurtry, William T Gerthoffer. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.
Journal of controlled release : official journal of the Controlled Release Society.
2015 Jul; 210(?):67-75. doi:
10.1016/j.jconrel.2015.05.261. [PMID: 25979327] - Adi Lahiani, Efrat Zahavi, Nir Netzer, Racheli Ofir, Lena Pinzur, Shani Raveh, Hadar Arien-Zakay, Ephraim Yavin, Philip Lazarovici. Human placental eXpanded (PLX) mesenchymal-like adherent stromal cells confer neuroprotection to nerve growth factor (NGF)-differentiated PC12 cells exposed to ischemia by secretion of IL-6 and VEGF.
Biochimica et biophysica acta.
2015 Feb; 1853(2):422-30. doi:
10.1016/j.bbamcr.2014.11.009. [PMID: 25450973] - Gregory P Star, Michele Giovinazzo, Esther Lamoureux, David Langleben. Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro.
Life sciences.
2014 Nov; 118(2):191-4. doi:
10.1016/j.lfs.2014.02.032. [PMID: 24607779] - Nathalie Mouraret, Elisabeth Marcos, Shariq Abid, Guillaume Gary-Bobo, Mirna Saker, Amal Houssaini, Jean-Luc Dubois-Rande, Laurent Boyer, Jorge Boczkowski, Geneviève Derumeaux, Valérie Amsellem, Serge Adnot. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.
Circulation.
2013 Apr; 127(16):1664-76. doi:
10.1161/circulationaha.113.002434. [PMID: 23513067] - Loredana Ciuclan, Martin J Hussey, Victoria Burton, Robert Good, Nicholas Duggan, Sarah Beach, Peter Jones, Roy Fox, Ieuan Clay, Olivier Bonneau, Irena Konstantinova, Andrew Pearce, David J Rowlands, Gabor Jarai, John Westwick, Margaret R MacLean, Matthew Thomas. Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
American journal of respiratory and critical care medicine.
2013 Jan; 187(1):78-89. doi:
10.1164/rccm.201206-1028oc. [PMID: 23087024] - Jamison J Grailer, Douglas A Steeber. Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone.
PloS one.
2013; 8(9):e75390. doi:
10.1371/journal.pone.0075390. [PMID: 24066177] - Sanjay Basak, Asim K Duttaroy. Leptin induces tube formation in first-trimester extravillous trophoblast cells.
European journal of obstetrics, gynecology, and reproductive biology.
2012 Sep; 164(1):24-9. doi:
10.1016/j.ejogrb.2012.05.033. [PMID: 22717511] - Kaikai Shen, Lili Ji, Bin Lu, Zhengtao Wang. c-Jun N-terminal kinase mediated VEGFR2 sustained phosphorylation is critical for VEGFA-induced angiogenesis in vitro and in vivo.
Cell biochemistry and biophysics.
2012 Sep; 64(1):17-27. doi:
10.1007/s12013-012-9363-0. [PMID: 22592917] - Yi Zhang, Guang Hu, Shang Li, Zhen Hua Li, Che Oi Lam, Si-Jia Hong, Yiu-Wa Kwan, Shun Wan Chan, George Pak-Heng Leung, Simon Ming-Yuen Lee. Pro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo.
Molecular medicine reports.
2012 03; 5(3):805-11. doi:
10.3892/mmr.2011.716. [PMID: 22179585] - Shuai Wang, Yi Li, Yun-Jian Huang. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
2011 Sep; 27(9):1003-6. doi:
NULL. [PMID: 21906476] - Carlo Spirli, Stefano Okolicsanyi, Romina Fiorotto, Luca Fabris, Massimiliano Cadamuro, Silvia Lecchi, Xin Tian, Stefan Somlo, Mario Strazzabosco. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.
Gastroenterology.
2010 Jan; 138(1):360-371.e7. doi:
10.1053/j.gastro.2009.09.005. [PMID: 19766642] - Torsten Kniess, Ralf Bergmann, Manuela Kuchar, Jörg Steinbach, Frank Wuest. Synthesis and radiopharmacological investigation of 3-[4'-[(18)F]fluorobenzylidene]indolin-2-one as possible tyrosine kinase inhibitor.
Bioorganic & medicinal chemistry.
2009 Nov; 17(22):7732-42. doi:
10.1016/j.bmc.2009.09.038. [PMID: 19822433] - Kelley S Brodsky, Ryan R McWilliams, Claudia R Amura, Nicholas P Barry, R Brian Doctor. Liver cyst cytokines promote endothelial cell proliferation and development.
Experimental biology and medicine (Maywood, N.J.).
2009 Oct; 234(10):1155-65. doi:
10.3181/0903-rm-112. [PMID: 19596832] - Jian-Wei Gu, R Davis Manning, Emily Young, Megan Shparago, Brandi Sartin, Amelia Purser Bailey. Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats.
American journal of physiology. Regulatory, integrative and comparative physiology.
2009 Jul; 297(1):R142-8. doi:
10.1152/ajpregu.90972.2008. [PMID: 19420288] - Shweta Mittar, Clare Ulyatt, Gareth J Howell, Alexander F Bruns, Ian Zachary, John H Walker, Sreenivasan Ponnambalam. VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent.
Experimental cell research.
2009 Mar; 315(5):877-89. doi:
10.1016/j.yexcr.2008.12.020. [PMID: 19162007] - Mark W Kieran, Jeffrey G Supko, Dana Wallace, Robert Fruscio, Tina Young Poussaint, Peter Phillips, Ian Pollack, Roger Packer, James M Boyett, Susan Blaney, Anu Banerjee, Russ Geyer, Henry Friedman, Stewart Goldman, Larry E Kun, Tobey Macdonald. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
Pediatric blood & cancer.
2009 Feb; 52(2):169-76. doi:
10.1002/pbc.21873. [PMID: 19065567] - Yasufumi Katanasaka, Tomoko Ida, Tomohiro Asai, Kosuke Shimizu, Fumiaki Koizumi, Noriyuki Maeda, Kazuhiko Baba, Naoto Oku. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Cancer letters.
2008 Nov; 270(2):260-8. doi:
10.1016/j.canlet.2008.05.009. [PMID: 18555591] - Qing Lu. Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5.
American journal of physiology. Lung cellular and molecular physiology.
2008 Jul; 295(1):L123-33. doi:
10.1152/ajplung.00402.2007. [PMID: 18456797] - Anne-Catherine Gérard, Sylvie Poncin, Bertrand Caetano, Pierre Sonveaux, Jean-Nicolas Audinot, Olivier Feron, Ides M Colin, Fabrice Soncin. Iodine deficiency induces a thyroid stimulating hormone-independent early phase of microvascular reshaping in the thyroid.
The American journal of pathology.
2008 Mar; 172(3):748-60. doi:
10.2353/ajpath.2008.070841. [PMID: 18276786] - Beth Overmoyer, Pingfu Fu, Charles Hoppel, Tomas Radivoyevitch, Robert Shenk, Marjie Persons, Paula Silverman, Kelly Robertson, Nicholas P Ziats, Jay K Wasman, Fadi W Abdul-Karim, John A Jesberger, Jeffrey Duerk, Paul Hartman, Shelli Hanks, Jonathan Lewin, Afshin Dowlati, Keith McCrae, Percy Ivy, Scot C Remick. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007 Oct; 13(19):5862-8. doi:
10.1158/1078-0432.ccr-07-0688. [PMID: 17908980] - Claudia R Amura, Kelley S Brodsky, Rachel Groff, Vincent H Gattone, Norbert F Voelkel, R Brian Doctor. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
American journal of physiology. Cell physiology.
2007 Jul; 293(1):C419-28. doi:
10.1152/ajpcell.00038.2007. [PMID: 17475663] - Hui Yu, Zhanli Wang, Liangren Zhang, Jufeng Zhang, Qian Huang. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Bioorganic & medicinal chemistry letters.
2007 Apr; 17(8):2126-33. doi:
10.1016/j.bmcl.2007.01.089. [PMID: 17306530] - Monica M Mita, Eric K Rowinsky, Leonardo Forero, S Gail Eckhart, Elzbieta Izbicka, Geoffrey R Weiss, Muralidhar Beeram, Alain C Mita, Johann S de Bono, Anthony W Tolcher, Lisa A Hammond, Paul Simmons, Kristin Berg, Chris Takimoto, Amita Patnaik. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer chemotherapy and pharmacology.
2007 Feb; 59(2):165-74. doi:
10.1007/s00280-006-0255-0. [PMID: 16736151] - Sun Hee Sung, Fuad N Ziyadeh, Amy Wang, Petr E Pyagay, Yashpal S Kanwar, Sheldon Chen. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Journal of the American Society of Nephrology : JASN.
2006 Nov; 17(11):3093-104. doi:
10.1681/asn.2006010064. [PMID: 16988063] - R R Foster, S C Satchell, J Seckley, M S Emmett, K Joory, C Y Xing, M A Saleem, P W Mathieson, D O Bates, S J Harper. VEGF-C promotes survival in podocytes.
American journal of physiology. Renal physiology.
2006 Jul; 291(1):F196-207. doi:
10.1152/ajprenal.00431.2005. [PMID: 16525158] - Marc Salzberg, Miklos Pless, Christoph Rochlitz, Klara Ambrus, Paul Scigalla, Richard Herrmann. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
Investigational new drugs.
2006 Jul; 24(4):299-304. doi:
10.1007/s10637-005-4061-z. [PMID: 16237511] - Albert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, Edwin Donnelly, Robert D Schumaker, Larry J Schaaf, Kenneth R Hande, Arthur C Fleischer, Alison L Hannah, Mace L Rothenberg. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
American journal of clinical oncology.
2006 Apr; 29(2):109-15. doi:
10.1097/01.coc.0000199882.53545.ac. [PMID: 16601426] - Mattias K Sköld, Mårten Risling, Staffan Holmin. Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration.
The European journal of neuroscience.
2006 Jan; 23(1):21-34. doi:
10.1111/j.1460-9568.2005.04527.x. [PMID: 16420412] - Anand Sistla, Narmada Shenoy. Reversible Z-E isomerism and pharmaceutical implications for SU5416.
Drug development and industrial pharmacy.
2005 Dec; 31(10):1001-7. doi:
10.1080/03639040500306260. [PMID: 16316856] - Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, John Waas, Nicholas P Ziats, Paul Hartman, Fadi W Abdul-Karim, Jay K Wasman, Jack Jesberger, Jonathan Lewin, Keith McCrae, Percy Ivy, Scot C Remick. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005 Nov; 11(21):7938-44. doi:
10.1158/1078-0432.ccr-04-2538. [PMID: 16278419] - Seiichiro Sakao, Laimute Taraseviciene-Stewart, Jong Deog Lee, Kathy Wood, Carlyne D Cool, Norbert F Voelkel. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2005 Jul; 19(9):1178-80. doi:
10.1096/fj.04-3261fje. [PMID: 15897232] - Yeping Zhao, Juthamas Sukbuntherng. Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS.
Journal of pharmaceutical and biomedical analysis.
2005 Jul; 38(3):479-86. doi:
10.1016/j.jpba.2005.01.029. [PMID: 15925249] - John V Heymach, Jayesh Desai, Judith Manola, Darren W Davis, David J McConkey, David Harmon, David P Ryan, Geraldine Goss, Travis Quigley, Annick D Van den Abbeele, Stuart G Silverman, Susan Connors, Judah Folkman, Christopher D M Fletcher, George D Demetri. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Sep; 10(17):5732-40. doi:
10.1158/1078-0432.ccr-04-0157. [PMID: 15355900] - Anne-Marie O'Farrell, Helene A Yuen, Beverly Smolich, Alison L Hannah, Sharianne G Louie, Weiru Hong, Alison T Stopeck, Lewis R Silverman, Jeffrey E Lancet, Judith E Karp, Maher Albitar, Julie M Cherrington, Francis J Giles. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research.
2004 Jul; 28(7):679-89. doi:
10.1016/j.leukres.2003.11.004. [PMID: 15158089] - Amy C Peterson, Susan Swiger, Walter M Stadler, Milica Medved, Greg Karczmar, Thomas F Gajewski. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Jun; 10(12 Pt 1):4048-54. doi:
10.1158/1078-0432.ccr-03-0766. [PMID: 15217937] - Tanyifor M Tohnya, Sonia Kim, Howard A Fine, Lara Dunn, William D Figg, Alex Sparreboom. Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2004 Jun; 805(1):135-40. doi:
10.1016/j.jchromb.2004.02.036. [PMID: 15113549] - Yeping Zhao, Juthamas Sukbuntherng, Lida Antonian. Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.
Journal of pharmaceutical and biomedical analysis.
2004 May; 35(3):513-22. doi:
10.1016/j.jpba.2003.08.017. [PMID: 15137976] - Walter M Stadler, Dingcai Cao, Nicholas J Vogelzang, Christopher W Ryan, Kristin Hoving, Russell Wright, Theodore Karrison, Everett E Vokes. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 May; 10(10):3365-70. doi:
10.1158/1078-0432.ccr-03-0404. [PMID: 15161690] - Ross R Jennens, Mark A Rosenthal, Geoffrey J Lindeman, Michael Michael. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
Urologic oncology.
2004 May; 22(3):193-6. doi:
10.1016/j.urolonc.2004.01.011. [PMID: 15271314] - Jamie Renbarger, Alexander Aleksic, Leticia McGuffey, Robert Dauser, Stacey Berg, Susan Blaney. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Cancer chemotherapy and pharmacology.
2004 Jan; 53(1):39-42. doi:
10.1007/s00280-003-0683-z. [PMID: 14551735] - Maurizio Zangari, Elias Anaissie, Alison Stopeck, Alyssa Morimoto, Nguyen Tan, Jeffrey Lancet, Maureen Cooper, Alison Hannah, Guillermo Garcia-Manero, Stephan Faderl, Hagop Kantarjian, Julie Cherrington, Maher Albitar, Francis J Giles. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Jan; 10(1 Pt 1):88-95. doi:
10.1158/1078-0432.ccr-0221-3. [PMID: 14734456] - Jiahuai Tan, Dennis E Hallahan. Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response.
Cancer research.
2003 Nov; 63(22):7663-7. doi:
NULL. [PMID: 14633687] - Primo N Lara, David I Quinn, Kim Margolin, Frederick J Meyers, Jeff Longmate, Paul Frankel, Philip C Mack, Corinne Turrell, Peter Valk, Jyotsna Rao, Penelope Buckley, Ted Wun, Robert Gosselin, Irina Galvin, Paul H Gumerlock, Heinz Josef Lenz, James H Doroshow, David R Gandara. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2003 Oct; 9(13):4772-81. doi:
NULL. [PMID: 14581348] - Jianguo Ma, Shaolan Li, Karin Reed, Ping Guo, James M Gallo. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
The Journal of pharmacology and experimental therapeutics.
2003 Jun; 305(3):833-9. doi:
10.1124/jpet.102.048587. [PMID: 12626639] - Bart C Kuenen, Jose Tabernero, Jose Baselga, Franco Cavalli, Elisabeth Pfanner, Pier Franco Conte, Siegfried Seeber, Srinivasan Madhusudan, Gael Deplanque, Holgen Huisman, Paul Scigalla, Klaas Hoekman, Adrian L Harris. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2003 May; 9(5):1648-55. doi:
NULL. [PMID: 12738717] - Raúl Gómez, Carlos Simón, José Remohí, Antonio Pellicer. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
Endocrinology.
2002 Nov; 143(11):4339-48. doi:
10.1210/en.2002-220204. [PMID: 12399430] - Chuenlei Parng, Wen Lin Seng, Carlos Semino, Patricia McGrath. Zebrafish: a preclinical model for drug screening.
Assay and drug development technologies.
2002 Nov; 1(1 Pt 1):41-8. doi:
10.1089/154065802761001293. [PMID: 15090155] - B C Kuenen, M Levi, J C M Meijers, A K Kakkar, V W M van Hinsbergh, P J Kostense, H M Pinedo, K Hoekman. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Arteriosclerosis, thrombosis, and vascular biology.
2002 Sep; 22(9):1500-5. doi:
10.1161/01.atv.0000030186.66672.36. [PMID: 12231573] - Alison Stopeck, Marrae Sheldon, Mahmood Vahedian, Gillian Cropp, Rishi Gosalia, Alison Hannah. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002 Sep; 8(9):2798-805. doi:
NULL. [PMID: 12231519] - Ulrika Bäckman, Asa Svensson, Rolf Christofferson. Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma.
Angiogenesis.
2002; 5(4):267-74. doi:
10.1023/a:1024564817563. [PMID: 12906318] - J Sukbuntherng, G Cropp, A Hannah, G S Wagner, L K Shawver, L Antonian. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.
The Journal of pharmacy and pharmacology.
2001 Dec; 53(12):1629-36. doi:
10.1211/0022357011778232. [PMID: 11804393] - Y Zhao, C Y Yang, J Haznedar, L Antonian. Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.
Journal of pharmaceutical and biomedical analysis.
2001 Jul; 25(5-6):821-32. doi:
10.1016/s0731-7085(01)00341-7. [PMID: 11377065] - G W Krystal, S Honsawek, D Kiewlich, C Liang, S Vasile, L Sun, G McMahon, K E Lipson. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Cancer research.
2001 May; 61(9):3660-8. doi:
. [PMID: 11325836] - D B Mendel, R E Schreck, D C West, G Li, L M Strawn, S S Tanciongco, S Vasile, L K Shawver, J M Cherrington. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2000 Dec; 6(12):4848-58. doi:
NULL. [PMID: 11156244] - A L Harris. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
The oncologist.
2000; 5 Suppl 1(?):32-6. doi:
10.1634/theoncologist.5-suppl_1-32. [PMID: 10804089] - L Sun, N Tran, C Liang, F Tang, A Rice, R Schreck, K Waltz, L K Shawver, G McMahon, C Tang. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Journal of medicinal chemistry.
1999 Dec; 42(25):5120-30. doi:
10.1021/jm9904295. [PMID: 10602697]